The partnership also allows Sanofi to use the company's adjuvant, Matrix-M ... One-trick pony? The Novavax logo displayed on ...
Novavax's stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for the year ...
For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...
Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the IAS Q3 ...
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...
A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...
“The development of Muse, a result of our ongoing collaboration with OpenAI and Formation Bio, represents another proof point ...
Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.
From the company's own site, we can see this pharma brand has a diversified portfolio of therapies across multiple clinical ...
The firm owned 44,289 shares of the company’s stock after acquiring an additional 8,494 shares during the quarter. Crossmark ...
The company is banking on revenue from its Sanofi deal and vaccines in development, including an experimental COVID-flu ...
abrdn plc reduced its holdings in Sanofi (NASDAQ:SNY – Free Report) by 30.4% during the third quarter, according to the company in its most recent filing with the SEC.The fund owned 250,085 ...